Statement on Takeda UK & Ireland Leadership

09 January 2019

 

High Wycombe, UK, 9 January 2019 - Following the completion of the Shire acquisition, Takeda UK & Ireland is pleased to announce Jon Neal as General Manager of the combined company.

Jon has been Managing Director of Takeda UK and Ireland since May 2018, having been with the company for a decade and bringing a wealth of experience in senior roles within the UK pharmaceutical industry.

Jon has been at the forefront of Takeda’s transformation and is delighted to be leading Takeda in the UK and Ireland through this exciting new phase.

Shane Ryan has been appointed as General Manager for Ireland. Shane brings over 20 years of pharmaceutical industry experience and was recently elected to the Irish Pharmaceutical Healthcare Association (IPHA).

 

Jon Neal, General Manager, Takeda UK and Ireland said:

“We are proud of our joint heritage in the UK and are excited by what our combined company can do with and for the NHS and patients. The UK and Ireland are significant markets for Takeda and we look forward to contributing to the UK and Ireland’s world-leading life sciences industry.

Takeda’s focus will be on ensuring our integration is smooth and beneficial to our customers and patients. I look forward to working closely with colleagues, partners and the NHS, always in the best interests of patients.”

 

Shane Ryan, General Manager, Takeda Ireland said:

“We have a deep and valued heritage in Ireland. Our new combined company will be in an even stronger position to deliver true value to patients, the healthcare ecosystem and society as a whole.

I am confident we have a strong future ahead of us.”

 

 

Contacts for media in UK and Ireland

For Takeda:

Audrey Liechti
Media in UK and Ireland
T: + 44 7787 445 369
audrey.liechti@takeda.com  

For Shire, now part of Takeda:

Freeha Rafiq
Shire Pharmaceuticals Ltd
Tel: + 44 7500 953 471
freeha.rafiq@takeda.com

 

About Takeda UK Ltd.

Takeda UK Ltd., located in High Wycombe, is the UK marketing and sales organisation of Takeda Pharmaceutical Company Limited, headquartered in Japan. Takeda Pharmaceutical Company Limited (TSE: 4502, NYSE:TAK) is a global, values-based, R&D-driven biopharmaceutical leader committed to bringing Better Health and a Brighter Future to patients by translating science into highly-innovative medicines. Takeda focuses its R&D efforts on on four therapeutic areas: Oncology, Gastroenterology (GI), Neuroscience and Rare Diseases. We also make targeted R&D investments in Plasma-Derived Therapies and Vaccines. We are focusing on developing highly innovative medicines that contribute to making a difference in people's lives by advancing the frontier of new treatment options and leveraging our enhanced collaborative R&D engine and capabilities to create a robust, modality-diverse pipeline. Our employees are committed to improving quality of life for patients and to working with our partners in health care in approximately 80 countries and regions.

 

 

Download full press release
View Takeda's press release relating to the completion of the Shire acqusition

 

 

 

UK/TUK/1901/0002
Date of Preparation: January 2019